Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1252W HIGH $1.46
Volume
1.23 M
Value Traded
315.16 K
Short % Float
4.42%
Days to Cover
2.2
+13.73%Week
-47.6%1 Month
-48.11%3 Month
-69.57%6 Month
-93.2%5 Year
-98.54%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.74 M
EPS (TTM)
-0.41
P/E Ratio
-
Ent. Value
125.48 M
Total Shares
119.44 M
Float Shares
114.22 M
Insiders
4.46%
Institutions
44.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ARAY Catalyst Timeline
Dated clinical, regulatory and corporate events for Accuray Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Accuray Incorporated
686Total events
7Upcoming
94Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Corporate ApprovalCorporate
Stockholders approve all proposals at Special Meeting enabling TCW financing transaction
●Management ChangeCorporate
Richard A. 'Randy' Meier appointed to board of directors, effective immediately
●Reverse Stock SplitCorporate
Stockholders approve reverse stock split at ratio between 1-for-15 and 1-for-40
●Oral PresentationPresentation
Accuray clinical session at ASTRO featuring Jonathan Lischalk, MD
▲Partnership / LicenseCorporate
Accuray enters agreements with Samsung NeuroLogica for volumetric imaging on CyberKnife System
▲Partnership / LicenseCorporate
Accuray and RaySearch enter definitive agreement for expanded collaboration on online adaptive radiation therapy
●Quarterly UpdateCorporate
Company not providing formal revenue or Adjusted EBITDA guidance for fiscal 2027
▲Debt Royalty FinancingCorporate
Comprehensive financing transaction with TCW Asset Management announced
▲Debt Royalty FinancingCorporate
TCW agreements: debt exchange, equity investment, delayed draw loan
▲Partnership / LicenseCorporate
TCS partnership expansion: finalized onboard remote diagnostics
●Quarterly UpdateCorporate
Announced plan for financial strengthening, partnerships, technology rollouts
▲Manufacturing MilestoneSynchronyApprovedCMC / Inspection
Synchrony Motion Management rollout
▲Partnership / LicenseCorporate
Definitive agreements with TCW announced as part of comprehensive financial plan
▲Partnership / LicenseCorporate
10-year strategic collaboration with University of Wisconsin-Madison to advance personalized cancer treatments using Stellar adaptive radiation therapy platform
cancersource ↗
◆Management ChangeCorporate
Appointment of Paul Miele as Senior Vice President and Chief Commercial Officer
◆Quarterly UpdateCorporate
Fiscal 2026 first quarter financial results expected to be released on November 5, 2025
◆Management ChangeCorporate
Suzanne Winter to retire as President and CEO, advisory role through end of November 2025
◆Quarterly UpdateCorporate
Preliminary fiscal 2026 first quarter financial results: total revenues $92.5-$94M, adjusted EBITDA ~($4)M
▲First Patient DosedTrial
First SBRT treatments using CyberKnife S7 System in Melbourne, Australia
cancersource ↗
▲Partnership / LicenseCorporate
Accuray and University of Wisconsin-Madison sign MOU to advance online adaptive radiotherapy
cancersource ↗
◆Oral PresentationPresentation
U.S. unveiling at ASTRO 2025 Annual Meeting
cancer (radiotherapy)source ↗
◆Debt Royalty FinancingCorporate
New $190M senior secured credit facilities (term loans, delayed draw, revolver)
◆Oral PresentationPresentation
Accuray management to participate in Jefferies Global Healthcare Conference 2025 fireside chat
▲Oral PresentationPresentation
Retrospective analysis of CyberKnife SBRT in high-risk prostate cancer presented at ESTRO 2025
prostate cancersource ↗
▲First Patient DosedTrial
First SRS/SBRT patient treatments in Austria with CyberKnife System
cancersource ↗
▼Quarterly UpdateCorporate
Fiscal Year 2025 Revenue Guidance Adjusted Downward Due to Tariffs
▲Oral PresentationPresentation
Donut-shaped circumferential SBRT using CyberKnife System for spinal metastases presented at RSS 2025
spinal metastasessource ↗
◆Oral PresentationPresentation
Accuray management fireside chat at 37th Annual Roth Conference
Past FDA Catalysts and PDUFA Decisions
How ARAY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 92%
Micro Cap(rank 605 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ARAY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CyberKnife System | prostate cancer | 2025-05-07 | 262 men over the age of 70 or with severe comorbidities; median follow-up of 39 months; 51 patients with a median follow up of 16 monthsRead More | Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Miele Paul MichaelOfficer (SVP, Chief Commercial Officer) | Grant/Award | 650,000 650,000 held | $0.00 | 05/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARAY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.1 % | 433.24 K | 1.68 M |
ARAY Institutional Ownership Trends
ARAY Short Interest
Shares sold short, counted twice a month.
4.42%
Short % of Float
of tradable shares sold short
5.0M
Shares Sold Short
-31.7% vs prior count
2.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARAY ranks across every disease it competes in
Competitive Position is a premium feature
See how ARAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARAY News
ARAY▼ -1.9%today
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray Incorporated announced the granting of equity inducement awards to Sofiane Laoussadi, its new Senior Vice President, Global Services & Solutions. The awards include 650,000 restricted stock units and 650,000 performance-based restricted stock units, effective October 30, 2026. Vesting is contingent on continued service and performance criteria.
Read more →ARAYAccuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026
Accuray Incorporated reported it will release first quarter fiscal 2027 financial results for the period ending September 30, 2026. Management will host a conference call at 1:30 p.m. PT on November 4, 2026. The company provided dial-in numbers for US and international participants. A live webcast and replay will be available via the investor relations website.
Read more →ARAYAccuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
Accuray Incorporated announced that stockholders approved key financing proposals at a Special Meeting, enabling the company to proceed with a transaction with TCW Asset Management. This includes a $40 million debt exchange for convertible preferred stock and a $15 million equity investment. Additionally, Richard A. Meier was appointed to the board, bringing extensive experience in healthcare leadership.
Read more →ARAY▲ +39.4%on this news
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
Accuray has partnered with Samsung NeuroLogica to enhance volumetric imaging for its CyberKnife System. This collaboration, announced during the ASTRO Annual Meeting, aims to improve treatment efficiency and decision-making through advanced imaging capabilities. Clinicians emphasize the importance of better visualization of patient anatomy, which could lead to more informed treatment decisions. The partnership reflects Accuray's strategy to innovate through targeted collaborations.
Read more →ARAYAccuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
Accuray and RaySearch Laboratories have entered into a collaboration to enhance online adaptive radiation therapy. The partnership focuses on integrating RayStation software with Accuray's platforms, starting with Radixact and extending to CyberKnife. This initiative aims to improve treatment personalization and efficiency, with Accuray committing to an $8 million purchase of RayStation licenses.
Read more →ARAYAccuray Reports Fourth Quarter and Fiscal 2026 Financial Results
Accuray Incorporated reported its financial results for the fourth quarter and fiscal year 2026, highlighting a successful transformation plan that exceeded cost improvement targets. Despite a 21% decrease in total net revenue and a net loss of $1.9 million, the company experienced growth in service revenue and expanded its strategic partnerships. Management expressed optimism for fiscal 2027, focusing on sustainable revenue growth and financial flexibility.
Read more →ARAYAccuray Advances Strategic Priorities Through Key Executive Leadership Appointments
Accuray has appointed Todd Brown and Sofiane Laoussadi to key leadership roles to enhance operational execution and customer value. Brown will lead the new Enterprise Performance Optimization organization, while Laoussadi will oversee global services. These appointments are part of Accuray's transformation strategy aimed at achieving sustainable growth and improving overall enterprise performance.
Read more →ARAYAccuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated will report its fourth quarter financial results for fiscal year 2026 on August 19, 2026. The results will be discussed during a conference call at 1:30 p.m. PT. A live webcast will also be available on the company's Investor Relations website. The company emphasizes its commitment to innovation in radiation therapy.
Read more →ARAY▲ +23.4%on this news· ran to +35% by day 3
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
Accuray Incorporated has announced a comprehensive plan to enhance its financial position and operational strategy. The plan includes agreements with TCW Asset Management for debt restructuring and additional liquidity, alongside strategic partnerships to boost innovation. The company is also focusing on differentiated technology and improving operational efficiency to drive long-term value creation.
Read more →ARAY▼ -5.2%on this news· ran to +17% by day 3
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Accuray Incorporated and the University of Wisconsin-Madison have entered a 10-year strategic collaboration to enhance personalized cancer treatments using Accuray's adaptive radiation therapy platform. This partnership aims to advance clinical research, education, and the development of innovative therapies, building on a successful history of collaboration in radiation medicine. The agreement seeks to improve patient care by leveraging both organizations' strengths.
Read more →ARAYAccuray Reports Fiscal 2026 Third Quarter Financial Results
Accuray Incorporated reported its third quarter financial results for fiscal 2026, revealing a 7% decrease in total net revenue compared to the previous year. The company has made progress with its transformation plan, achieving $10 million in cost improvements. However, geopolitical uncertainties have led to the withdrawal of its financial guidance, impacting product shipments and service revenues. The net loss for the quarter increased to $11.8 million.
Read more →ARAY▲ +11%on this news
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray Incorporated will announce its financial results for the third quarter of fiscal 2026 on May 6, 2026. The conference call will be hosted by company management and will include options for both live participation and replay. Accuray emphasizes its commitment to innovation in radiation therapy, aiming to enhance patient care.
Read more →ARAYAccuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele, who has extensive experience in global commercial leadership, will oversee Accuray's global commercialization strategy. His appointment is expected to enhance the company's commercial performance and drive growth in systems and services sales.
Read more →ARAY▼ -20.7%on this newsshared move
Accuray Reports Fiscal 2026 Second Quarter Financial Results
Accuray Incorporated reported its fiscal 2026 second quarter results, revealing a 12% decline in total net revenue to $102.2 million. Despite a 4% increase in service revenue, product revenue fell by 26%. The company is undergoing a transformation aimed at enhancing growth and profitability, with CEO Steve La Neve expressing confidence in the strategic changes being implemented.
Read more →ARAYAccuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated will announce its financial results for the second quarter of fiscal 2026 on February 4, 2026. The results will be discussed during a conference call at 1:30 p.m. PT. Investors can access the call via dial-in numbers or a live webcast. A replay will be available for one week after the call.
Read more →ARAYAccuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Accuray Incorporated has announced the first phase of its strategic transformation plan, aiming to enhance operational efficiency and accountability. This initiative is projected to improve annualized operating profitability by around $25 million. The plan includes workforce reductions and restructuring costs, with full implementation expected by the end of fiscal 2026. Accuray maintains its forecasts for the fiscal year despite these changes.
Read more →ARAY▼ -15.9%on this news
Accuray Reports Fiscal 2026 First Quarter Financial Results
Accuray Incorporated reported its fiscal 2026 first quarter financial results, showing a 7% decrease in total net revenue to $93.9 million. Despite a decline in product revenue, the company noted growth in service revenue and ongoing expansion of its CyberKnife and Radixact systems. The net loss widened significantly compared to the previous year, prompting the company to reaffirm its financial guidance for the year.
Read more →ARAYAccuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
Accuray Incorporated will announce its first quarter fiscal 2026 financial results on November 5, 2025. The results will be discussed during a conference call at 1:30 p.m. PT/4:30 p.m. ET. A live webcast will also be available, along with a replay for those unable to attend the live event.
Read more →About Accuray Incorporated
Headquarters1240 DEMING WAY, MADISON, WI, 53717
Founded1990
BIOPHARMAWATCH ELITE PLUS
Trade the next ARAY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime